Skip to content

The effect of Dydrogesterone and micronized progesterone on threatend abortion

The comparison between the effect of Dydrogesterone and micronized progesterone intake on consequences of pregnancy in threatend abortion.

Status
Recruiting
Phases
Phase 3
Study type
Interventional
Source
IRCT
Registry ID
IRCT20120104008611N10
Enrollment
200
Registered
2020-01-31
Start date
2019-10-22
Completion date
Unknown
Last updated
2020-02-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Threatened abortion. Threatened abortion

Interventions

Intervention 1: Intervention group 1: Didrogesterone tablet made by Abourihan Company, 10 mg twice a day (10 mg every 12 hours ) since the initial of the study up until one week after bleeding. Interv

Sponsors

Qazvin University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
18 Years to 35 Years

Inclusion criteria

Inclusion criteria: Gestational age 6 to 13 weeks Observation of fetal heart rate Vaginal bleeding Absence of uterine anomalies Absence fetal anomalies

Exclusion criteria

Exclusion criteria: Breast carcinoma Severe liver problems Genital carcinoma Thromboembolic disorders Epilepsy Diabetes Hypertension

Design outcomes

Primary

MeasureTime frame
Preeclampsia. Timepoint: Up to 28 weeks monthly and until 36 weeks every two weeks and thereafter weekly until delivery. Method of measurement: Sphygmometer.;Gestational Diabetes. Timepoint: Up to 28 weeks monthly and until 36 weeks every two weeks and then weekly until delivery. Method of measurement: Glucose tolerance test.;Preterm labor. Timepoint: Up to 28 weeks monthly and until 36 weeks every two weeks and then weekly until delivery. Method of measurement: Tocometry of uterus and delivery before 37 weeks of pregnancy.;Low birth weight. Timepoint: Weight immediately after birth. Method of measurement: Pediatric scales.;Abortion under 20 weeks of pregnancy. Timepoint: Every week from the start of the intervention up to 20 weeks of pregnancy. Method of measurement: Questionnaire.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr Hamide pakniat

Qazvin University of Medical Sciences

pakniat110@yahoo.com+98 28 3323 6374

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026